OUR BLOG
Insights
-
John Cassidy, CEO of Cambridge Cancer Genomics, on AI-Powered Disease Prediction for Oncology
For this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with John Cassidy, CEO of Cambridge Cancer Genomics. CCG is using liquid biopsy, genomics, and artificial intelligence to predict cancer disease progression and improve its treatment.
-
Kristen Fortney, CEO of BioAge Labs, on AI for Aging Research
For this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with Kristen Fortney, founder and CEO of BioAge Labs. Kristen leads one of just a few companies focused explicitly on aging itself, rather than just the diseases for which aging puts people at greater risk.
-
Immunohistochemistry (IHC): Principles & Factors to Consider For Quality Results
We break down each steps involved in a immunostaining (immunohistochemistry or immunofluorescence) experiment and discuss the principles and factors to consider for quality results.
-
Sam Cooper, CEO of Phenomic AI, on Automated HCS and More
For this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with Sam Cooper, cofounder and CEO of Phenomic AI. Sam and his team use machine learning for automated image analysis to study cell biology and screen drugs. But that’s just the beginning.
-
Shai Shen-Orr, Chief Scientist of CytoReason, on AI for Systems Immunology
For this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with Shai Shen-Orr, chief scientist of CytoReason, about systems immunology, its potential in medicine, and how CytoReason applies artificial intelligence to make sense of the growing body of immune-related data.
-
Leila Pirhaji, CEO of ReviveMed, on AI for Metabolomics
For this episode of the Artificial Intelligence in Drug Discovery podcast, I spoke with Leila Pirhaji of ReviveMed about metabolomics for diagnosis and treatment, and how ReviveMed is using AI to realize its potential.
-
Mammalian Model Organisms: Contributions and Limitations
We discuss the pros and cons of the top 3 commonly used mammalian model organisms in biomedical research.
-
Dr. David Rimm on Antibodies, Reproducibility, and His Experience with BenchSci
Dr. David Rimm, Professor at Yale University, shares his perspectives on the challenges of finding antibodies, and how BenchSci has helped.
-
The Current State of Alzheimer’s Disease Biomarkers
Much of neuroscience research efforts has been devoted to Alzheimer’s Disease. Here we summarize what is currently known about the biomarkers for Alzheimer’s.